These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Dengue fever: from disease to vaccination]. Teyssou R Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380 [TBL] [Abstract][Full Text] [Related]
3. [Towards a new vaccine economy?]. Poirot P; Martin JF Sante; 1994; 4(3):183-7. PubMed ID: 7921683 [TBL] [Abstract][Full Text] [Related]
4. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. Chen RT Vaccine; 2004 May; 22(15-16):2047-53. PubMed ID: 15121321 [TBL] [Abstract][Full Text] [Related]
6. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. Patel MM; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612 [TBL] [Abstract][Full Text] [Related]
8. Preventive vaccines against bioterrorism: evaluation of efficacy and safety. Horne AD; Clifford J; Goldenthal KL; Kleppinger C; Lachenbruch PA Vaccine; 2004 Nov; 23(1):84-90. PubMed ID: 15519711 [TBL] [Abstract][Full Text] [Related]
9. Assuring the quality, safety, and efficacy of DNA vaccines. Robertson JS; Griffiths E Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863 [TBL] [Abstract][Full Text] [Related]
10. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Jadhav SS; Gautam M; Gairola S Biologicals; 2009 Jun; 37(3):165-8. PubMed ID: 19328010 [TBL] [Abstract][Full Text] [Related]
11. Paying for the dream. CVI Forum; 1994 Nov; (8):2-5. PubMed ID: 12348743 [TBL] [Abstract][Full Text] [Related]
12. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Schuchat A; Bell BP Expert Rev Vaccines; 2008 May; 7(4):437-56. PubMed ID: 18444891 [TBL] [Abstract][Full Text] [Related]
13. Issues in the design and implementation of vaccine trials in less developed countries. Deen JL; Clemens JD Nat Rev Drug Discov; 2006 Nov; 5(11):932-40. PubMed ID: 17080029 [TBL] [Abstract][Full Text] [Related]
15. The impact of globalization on vaccine development and availability. Milstien JB; Kaddar M; Kieny MP Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187 [TBL] [Abstract][Full Text] [Related]
16. Why certain vaccines have been delayed or not developed at all. Plotkin SA Health Aff (Millwood); 2005; 24(3):631-4. PubMed ID: 15886153 [TBL] [Abstract][Full Text] [Related]
17. Glovax's perspective: opportunities and approaches to vaccine business in Asia. Shin SH Dev Biol (Basel); 2002; 110():31-4. PubMed ID: 12477304 [TBL] [Abstract][Full Text] [Related]
18. Assuring the quality, safety, and efficacy of DNA vaccines. Robertson JS; Griffiths E Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466 [TBL] [Abstract][Full Text] [Related]
19. Difficulties associated with the development and licensing of vaccines for protection against bio-warfare and bio-terrorism. Langford MJ; Myers RC Dev Biol (Basel); 2002; 110():107-12. PubMed ID: 12477313 [TBL] [Abstract][Full Text] [Related]
20. Are economic evaluations an important tool in vaccine policy decisions? Jacobs P Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):507-11. PubMed ID: 21958095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]